spironolactone has been researched along with valine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (77.27) | 29.6817 |
| 2010's | 4 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arant, BS; Brackett, NC; Still, WJ; Young, RB | 1 |
| Bertanelli, F; Leone, A; Mori, L | 1 |
| Bieringer, M; Breu, V; Dechend, R; Fiebeler, A; Haller, H; Luft, FC; Müller, DN; Park, JK; Schmidt, F; Shagdarsuren, E | 1 |
| Miller, AB; Srivastava, P | 1 |
| Armstrong, PW; Borer, J; Fleming, T; Lipicky, R | 1 |
| Piérard, L | 1 |
| Fakouhi, K; He, W; Krause, S; Krum, H; Nolly, H; Roniker, B; Workman, D | 1 |
| Huang, CX; Jiang, H; Jiang, XJ; Liang, YH; Wang, JM; Zhou, Y | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, L; Hobbs, FD; Krum, H; Maggioni, A; McKelvie, RS; McMurray, J; Piña, IL; Soler-Soler, J; Swedberg, K | 1 |
| Drexler, H; Landmesser, U | 1 |
| Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T | 1 |
| Akdag, I; Filiz, G; Gullulu, M; Kahvecioglu, S; Savci, V | 1 |
| Imamoto, S; Kuno, M; Mochizuki, S; Nagai, M; Okada, T; Seki, S; Taniguchi, I; Taniguchi, M | 1 |
| Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K | 1 |
| Kushibiki, M; Okumura, K; Osanai, T; Tomita, H; Yamada, M | 1 |
| Ge, Y; Huang, Y; Kohan, DE | 1 |
| Harbig, J; Jaworski, K; Miller, AG; Tan, G; Wilkinson-Berka, JL | 1 |
| Fukuda, N; Fukushima, H; Hirata, H; Ishimitsu, T; Kobayashi, E; Kobayashi, N; Koguchi, W; Machida, Y; Mamada, Y; Suzuki, N; Tabei, K; Takeshima, H; Yokotsuka, F | 1 |
| Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Sakata, A; Tsukuda, K | 1 |
| Einecke, D | 1 |
| Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM | 1 |
2 review(s) available for spironolactone and valine
| Article | Year |
|---|---|
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Heart Failure; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2001 |
Chronic heart failure: an overview of conventional treatment versus novel approaches.
Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cardiac Glycosides; Erythropoietin; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Pacemaker, Artificial; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2005 |
2 trial(s) available for spironolactone and valine
| Article | Year |
|---|---|
Treatment of hypertension with valsartan combined with spironolactone.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Spironolactone; Tetrazoles; Valine; Valsartan | 2000 |
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Patient Dropouts; Renin-Angiotensin System; Spironolactone; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
18 other study(ies) available for spironolactone and valine
| Article | Year |
|---|---|
Case studies of siblings with juxtaglomerular hyperplasia and secondary aldosteronism associated with severe azotemia and renal rickets--Bartter's syndrome or disease?
Topics: Aldosterone; Alkalosis; Angiotensin II; Bone Diseases; Child; Child, Preschool; Humans; Hyperaldosteronism; Hyperplasia; Hypertrophy; Hypokalemia; Juxtaglomerular Apparatus; Kidney Diseases; Kidney Glomerulus; Male; Spironolactone; Triamterene; Valine | 1970 |
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; Body Weight; Cardiovascular Diseases; Fibroblast Growth Factor 2; Heart; Immunohistochemistry; Mineralocorticoid Receptor Antagonists; NF-kappa B; Organ Size; Platelet-Derived Growth Factor; Rats; Receptors, Mineralocorticoid; Renin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Transcription Factor AP-1; Transforming Growth Factor beta; Valine; Valsartan | 2001 |
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black People; Canada; Cardiovascular Agents; Drug Approval; Heart Failure; Humans; Hyperkalemia; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renal Insufficiency; Spironolactone; Survival Rate; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2001 |
[Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Spironolactone; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2002 |
Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Central Venous Pressure; Chromatography, High Pressure Liquid; Collagen; Heart; Hydroxyproline; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Organ Size; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2004 |
[Hyperkalemia. Main symptoms: muscle weakness, cardiac arrhythmias].
Topics: Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Heart Failure; Humans; Hyperkalemia; Hypertension; Male; Middle Aged; Muscle Weakness; Spironolactone; Tetrazoles; Valine; Valsartan | 2004 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzopyrans; Biphenyl Compounds; Bisoprolol; Captopril; Carbazoles; Carvedilol; Drug Therapy, Combination; Enalapril; Ethanolamines; Evidence-Based Medicine; Guideline Adherence; Heart Failure; Humans; Indoles; Lisinopril; Metoprolol; Mineralocorticoid Receptor Antagonists; Nebivolol; Practice Guidelines as Topic; Propanolamines; Ramipril; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan | 2005 |
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Cholesterol, Dietary; Diet, Atherogenic; Enzyme Activation; Eplerenone; Inflammation; Male; Mice; Muscle, Smooth, Vascular; NADPH Oxidases; Oxidative Stress; Spironolactone; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2006 |
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Proliferation; Disease Models, Animal; Diuretics; Fibrosis; Glomerulonephritis, Membranoproliferative; Ki-67 Antigen; Kidney; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Spironolactone; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2006 |
Combined treatment with valsartan and spironolactone prevents cardiovascular remodeling in renovascular hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Physiological Phenomena; Hypertension, Renovascular; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Rats; Rats, Wistar; Spironolactone; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2006 |
Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Thoracic; beta-Galactosidase; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Male; Muscle, Smooth, Vascular; Oxidative Stress; Proto-Oncogene Proteins p21(ras); Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Renin-Angiotensin System; RNA, Small Interfering; Spironolactone; Tetrazoles; Tumor Suppressor Protein p53; Valine; Valsartan | 2007 |
Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Biphenyl Compounds; Dimerization; Eplerenone; Male; Mesentery; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Receptor, Angiotensin, Type 1; Spironolactone; Tetrazoles; Transglutaminases; Valine; Valsartan; Vasoconstriction; Vasodilation | 2008 |
Role of the renin-angiotensin-aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Blood Pressure; DNA Primers; Endothelin-1; Female; Hypertension; Kidney Tubules, Collecting; Male; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2008 |
Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology.
Topics: Aldosterone; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Cattle; Cells, Cultured; Cytokines; Endothelial Cells; Eye Proteins; Glucosephosphate Dehydrogenase; Leukostasis; Mineralocorticoid Receptor Antagonists; NADPH Oxidase 4; NADPH Oxidases; Neovascularization, Pathologic; Oxidative Stress; Oxygen; Pericytes; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Renin-Angiotensin System; Retinal Vasculitis; Sodium Chloride; Spironolactone; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2009 |
Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb.
Topics: Angiopoietin-1; Angiopoietin-2; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Endothelial Cells; Eplerenone; Hindlimb; Immediate-Early Proteins; Ischemia; Male; Mineralocorticoid Receptor Antagonists; Monocytes; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Spironolactone; Stem Cells; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factors | 2010 |
Angiotensin II and aldosterone-induced neuronal damage in neurons through an astrocyte-dependent mechanism.
Topics: Aldosterone; Angiotensin II; Animals; Astrocytes; Cells, Cultured; DNA Damage; Eplerenone; Ganglia, Spinal; Mice; Mice, Inbred C57BL; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone; Tetrazoles; Valine; Valsartan | 2011 |
[2 promising substances for diastolic heart failure].
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure, Diastolic; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Spironolactone; Tetrazoles; Valine; Valsartan | 2012 |
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, Animal; Down-Regulation; Heart Failure; Isoproterenol; Male; Myocytes, Cardiac; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Valine; Valsartan | 2013 |